Joanne F Chou, MPH

Research Biostatistician II

Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Departmental Newsletter
Career Opportunities
Quantitative Sciences Undergraduate Research Experience (QSURE)
Software
Bridge to Biostats

Joanne F Chou, MPH

Research Biostatistician II

Share
Print
Share
Print
Joanne Chou, MPH

Office Phone

646-888-8288

Email

chouj@mskcc.org

Education

Columbia University

I joined department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center (MSKCC) in the summer of 2016. My main collaborations at MSKCC are with oncologists from the gastrointestinal service, surgeons from both Colorectal (CRC) and Hepatopancreatobillary (HPB) services, and investigators in the cancer survivorship program through the St. Jude’s Childhood Cancer Survivorship group (CCSS). 

My primary interests focus on developing and validating prediction models to predict patient outcomes and identify useful biomarkers that can help with cancer screening. In addition, I’m also interested in new methodology in clinical trial design, particularly in the field of immunotherapy.

Publications

Selected Publications

  1. O’Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. (2020).  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin with or without Veliparib in Patients With Pancreatic Adenocarcinoma and a Germline BRCA/PALB2 Mutations. Journal of Clinical Oncology in print.
  2. Moskowitz CS, Chou JF, Neglia JP, Partridge AH, Howell RM, Diller LR, Novetsky Friedman D, Barnea D, Morton LM, Turcotte LM, Arnold MA, Leisenring WM, Armstrong GT, Robison LL, Oeffinger KC, Henderson TO. (2019). Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 37(24),2120-2130.
  3. Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D’Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR. (2019). Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology in print.
  4. Oeffinger KC, Ford JS, Moskowitz CS, Chou JF, Henderson TO, Hudson MM, Diller L, McDonald A, Ford J, Mubdi NZ, Rinehart D, Vukadinovich C, Gibson TM, Anderson N, Elkin EB, Garrett K, Rebull M, Leisenring W, Robison LL, Armstrong GT. (2019). Promoting Breast Cancer Surveillance: The EMPOWER Study a Randomized Clinical Trial in the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 37(24),2131-2140.
  5. Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, Turcotte S, Vandenbroucke-Menu F, Lapointe R, Buettner S, Groot Koerkamp B, Ijzermans JNM, Chan CY, Goh BKP, Teo JY, Kam JH, Jeyaraj PR, Cheow PC, Chung AYF, Chow PKH, Ooi LLPJ, Balachandran VP, Kingham TP, Allen PJ, D’Angelica MI, DeMatteo RP, Jarnagin WR, Lee SY. (2017). Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Annals of Surgery, 266(4),693-701.